Intellectual Property India Publishes Patent Application for Novel Invariant Natural Killer T Cells And T Cell Engager Compositions And Methods Of Use Thereof

MUMBAI, India, Aug. 12 -- Intellectual Property India has published a patent application (202617054280 A) filed by Mink Therapeutics, Inc. on April 28, 2026, for Novel Invariant Natural Killer T Cells And T Cell Engager Compositions And Methods Of Use Thereof.

Inventors include Van Dijk, Marc; Chantzoura, Eleni; Popis, Martyna; Altman-Sharoni, Efrat; and Niedzielska, Magdalena.

The application for the patent was published on August 07, 2026, under issue no. 32/2026.

Abstract: Provided are novel compositions comprising natural killer T cells ("NKT cells") and T cell engagers. In certain embodiments, NKT cells are allogeneic invariant natural killer T cells ("iNKT cells") and the T cell engager is a bispecific or multispecific antibody comprising a CD3 binding domain and a tumor antigen binding domain. The invention includes methods of treating cancer comprising administering to a subject in need NKT cells (e.g., allogeneic iNKT cells) and a T cell engager.

Disclaimer: Curated by HT Syndication.